Pharvaris N.V. PHVS
34.10 USD -0.68 (-1.96%)
Nov 4, 2026, 2:02 PM EST
33.03 Day range 35.42
21.02 52-week range 43.25
- YTD
- +22.88%
- 1 year
- +57.58%
News
benzinga.com This Monolithic Power Analyst Turns Bullish; Here Are Top 4 Upgrades For Friday Analysts upgraded Incyte, Intel, Rivian and Monolithic Power, raising ratings and targets; MPWR’s target increased to $1,700.
benzinga.com This Hilton Hotels Analyst Turns Bullish; Here Are Top 5 Upgrades For Thursday Analysts upgraded VF Corp, Hilton, Ares Capital, eBay and Wintrust Financial, raising targets for VF, Hilton, eBay and Wintrust.
globenewswire.com Pharvaris to Present Clinical and Real-World Data at the ACAAI 2026 Annual Scientific Meeting Pivotal, Phase 3 CHAPTER-3 data selected for late-breaking oral presentation on Saturday, November 14 Pivotal, Phase 3 CHAPTER-3 data selected for late-breaking oral presentation on Saturday,…
benzinga.com This Pentair Analyst Is No Longer Bearish; Here Are Top 2 Upgrades For Wednesday Analysts upgraded Pentair to Neutral with a $65 target and Sun Life Financial to Outperform, raising its target to C$122.
benzinga.com This Tesla Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday Analysts upgraded SAFE, CNOB, LMT and more.
benzinga.com Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade Bank of America Securities on Friday upgraded Pharvaris N.V. (NASDAQ:PHVS), citing an attractive entry point with clinical risk largely removed.
benzinga.com Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade Bank of America upgrades Pharvaris to Buy with a new price target, citing reduced clinical risk for deucrictibant in hereditary angioedema despite market competition.
benzinga.com This Allegion Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings…
benzinga.com B of A Securities Upgrades Pharvaris to Buy, Maintains Price Target to $44 B of A Securities analyst Tazeen Ahmad upgrades Pharvaris (NASDAQ:PHVS) from Neutral to Buy and maintains the price target from $44 to $44.
benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session Gainers Pharvaris (NASDAQ:PHVS) stock moved upwards by 19.4% to $36.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.0 billion. CalciMedica (NASDAQ:CALC)…
benzinga.com Reported Earlier, Pharvaris Says Lancet-Published Phase 3 Data Show Deucrictibant IR Delivered Symptom Relief In 1.28 Hours And Complete Resolution In 11.95 Hours For HAE Attacks, With NDA And MAA Under Review Results from RAPIDe-3 demonstrate that treatment with deucrictibant IR resulted in faster time to onset of symptom relief (1.28 hours) and to complete symptom resolution (11.95 hours)Deucrictibant IR…
globenewswire.com Phase 3 Study Results Highlighting Deucrictibant's Rapid and Sustained Efficacy in Treating HAE Attacks Published in The Lancet ZUG, Switzerland, Oct. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of…
globenewswire.com Real-World Analysis Highlighting HAE Disease Experience and Gaps in Treatment Satisfaction Published in Advances in Therapy Findings highlight opportunities for further improvement in treatment use and adherence, despite the availability of multiple long-term prophylaxis and on-demand treatment options Findings highlight…
defenseworld.net Pharvaris (NASDAQ:PHVS) Director Robert Glassman Sells 14,493 Shares of Stock Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) Director Robert Glassman sold 14,493 shares of Pharvaris stock in a transaction dated Thursday, September 17th. The shares were sold at an average…
defenseworld.net Pharvaris (NASDAQ:PHVS) Insider Anne Lesage Sells 20,000 Shares Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) insider Anne Lesage sold 20,000 shares of the company's stock in a transaction on Thursday, September 17th. The shares were sold at an average price of…
defenseworld.net Anne Lesage Sells 30,000 Shares of Pharvaris (NASDAQ:PHVS) Stock Pharvaris N.V. (NASDAQ: PHVS - Get Free Report) insider Anne Lesage sold 30,000 shares of the company's stock in a transaction dated Thursday, September 10th. The stock was sold at an average price…
defenseworld.net Pharvaris N.V. $PHVS Position Trimmed by Squarepoint Ops LLC Squarepoint Ops LLC lowered its stake in Pharvaris N.V. (NASDAQ: PHVS) by 53.7% during the undefined quarter, according to its most recent Form 13F filing with the SEC. The institutional investor…
seekingalpha.com Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript Pharvaris N.V. (PHVS) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
zacks.com PHVS Stock Rises 10% in a Month: What Is Driving the Rally? Pharvaris gains as strong phase III data show deucrictibant XR reduces HAE attacks 83%, supporting plans for regulatory submissions in 2027.
benzinga.com Guggenheim Maintains Buy on Pharvaris, Raises Price Target to $44 Guggenheim analyst Debjit Chattopadhyay maintains Pharvaris (NASDAQ:PHVS) with a Buy and raises the price target from $40 to $44.
seekingalpha.com Pharvaris: 'Strong Buy' Based On Deucrictibant PDUFA And Prophylaxis Trial Win Pharvaris N.V. maintains a 'Strong Buy' rating following pivotal phase 3 wins for both on-demand and prophylactic HAE therapies. PHVS achieved rapid symptom relief in RAPIDe-3 [median 1.28 hours, p
benzinga.com Morgan Stanley Maintains Overweight on Pharvaris, Raises Price Target to $62 Morgan Stanley analyst Maxwell Skor maintains Pharvaris (NASDAQ:PHVS) with a Overweight and raises the price target from $46 to $62.- benzinga.com Leerink Partners Maintains Outperform on Pharvaris, Raises Price Target to $65 Leerink Partners analyst Joseph Schwartz maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the price target from $50 to $65.
benzinga.com Wells Fargo Maintains Overweight on Pharvaris, Raises Price Target to $65 Wells Fargo analyst Yanan Zhu maintains Pharvaris (NASDAQ:PHVS) with a Overweight and raises the price target from $55 to $65.
benzinga.com RBC Capital Maintains Outperform on Pharvaris, Raises Price Target to $62 RBC Capital analyst Nevin Varghese maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the price target from $52 to $62.- benzinga.com Citizens Maintains Market Outperform on Pharvaris, Raises Price Target to $79 Citizens analyst Jonathan Wolleben maintains Pharvaris (NASDAQ:PHVS) with a Market Outperform and raises the price target from $75 to $79.
benzinga.com Imax To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Wednesday Analysts cut targets for CAN, TTAN and BSX, while raising targets for BRZE, VRNS, IMAX, PHVS and CHYM. Ratings largely remained positive.- benzinga.com Wedbush Maintains Outperform on Pharvaris, Raises Price Target to $50 Wedbush analyst Laura Chico maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the price target from $42 to $50.
seekingalpha.com Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema Transcript Pharvaris N.V. (PHVS) Discusses Topline Results of Chapter-3 Phase III Study on Deucrictibant for Prophylactic Treatment of Hereditary Angioedema Transcript
benzinga.com Crude Oil Gains 1.5%; ABM Posts Upbeat Q3 Earnings U.S. stocks fell Tuesday as health care lagged, while energy gained. ABM beat estimates; oil rose, and several biotech shares surged or plunged.
benzinga.com HC Wainwright & Co. Reiterates Buy on Pharvaris, Maintains $60 Price Target HC Wainwright & Co. analyst Patrick R. Trucchio reiterates Pharvaris (NASDAQ:PHVS) with a Buy and maintains $60 price target.
benzinga.com Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday U.S. stocks fell Tuesday, but Roivant surged 16% on positive PH-ILD trial data. Pharvaris, Solaris, IonQ and quantum stocks also posted strong gains.
benzinga.com Why Is Pharvaris Stock Soaring Tuesday? Pharvaris (PHVS) stock surges 17% on positive Phase 3 HAE trial data. Deucrictibant XR reduced monthly attacks up to 87%.
benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session Gainers iSpecimen (NASDAQ:ISPC) stock increased by 22.7% to $1.89 during Tuesday's pre-market session. The company's market cap stands at $3.8 million. Bluejay Diagnostics (NASDAQ:BJDX) shares moved…
reuters.com Pharvaris' genetic disorder drug meets main goal in late-stage trial Pharvaris said on Tuesday its experimental oral drug helped prevent swelling attacks in patients with hereditary angioedema, meeting the main goal of a late-stage trial.- benzinga.com Pharvaris Announces Statistically Significant And Clinically Meaningful Topline Results From Its CHAPTER-3 Pivotal Phase 3 Study Evaluating Deucrictibant Extended-Release Tablet For Prevention Of HAE Attacks; Primary Endpoint And All Secondary Efficacy Endpoints Were Met With Statistical Significance Primary endpoint met: 83% attack rate reduction versus placebo (p<0.0001) in the first and only prophylaxis Phase 3 study in all three types of HAE87% attack rate reduction versus placebo observed in…
globenewswire.com Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks ZUG, Switzerland, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet…
marketbeat.com Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It Drug pricing is back on the front page, and healthcare investors have barely flinched. The White House's latest round of most-favored-nation pricing agreements brought nine more manufacturers into…
globenewswire.com Pharvaris Presents Translational, Nonclinical, and Clinical Data at Bradykinin Symposium 2026 ZUG, Switzerland, Sept. 03, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing oral bradykinin B2 receptor antagonists to help address unmet needs of…
defenseworld.net BlackRock Inc. Makes New Investment in Pharvaris N.V. $PHVS BlackRock Inc. purchased a new stake in shares of Pharvaris N.V. (NASDAQ: PHVS) during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The firm…
defenseworld.net 5AM Venture Management LLC Makes New $27.58 Billion Investment in Pharvaris N.V. $PHVS 5AM Venture Management LLC bought a new stake in shares of Pharvaris N.V. (NASDAQ: PHVS) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission.…- benzinga.com RBC Capital Maintains Outperform on Pharvaris, Raises Price Target to $52 RBC Capital analyst Brian Abrahams maintains Pharvaris (NASDAQ:PHVS) with a Outperform and raises the price target from $51 to $52.
benzinga.com Guggenheim Maintains Buy on Pharvaris, Raises Price Target to $40 Guggenheim analyst Debjit Chattopadhyay maintains Pharvaris (NASDAQ:PHVS) with a Buy and raises the price target from $39 to $40.- benzinga.com Citizens Maintains Market Outperform on Pharvaris, Raises Price Target to $75 Citizens analyst Jonathan Wolleben maintains Pharvaris (NASDAQ:PHVS) with a Market Outperform and raises the price target from $74 to $75.
- benzinga.com Pharvaris Q2 EPS $(0.81) Misses $(0.74) Estimate Pharvaris (NASDAQ:PHVS) reported quarterly losses of $(0.81) per share which missed the analyst consensus estimate of $(0.74) by 9.46 percent. This is a 13.83 percent increase over losses of $(0.94)…
globenewswire.com Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update ZUG, Switzerland, Aug. 12, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet…
globenewswire.com Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology ZUG, Switzerland, Aug. 06, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet…- benzinga.com Pharvaris Announces Publication Of Comprehensive Review On Bradykinin Biology And B2R Antagonism In Clinical Reviews In Allergy & Immunology Provides a state-of-the-art overview of the evidence on the critical role of bradykinin B2 receptor in the pathogenesis of bradykinin-mediated angioedemaExplains the scientific foundation for…
- benzinga.com Wells Fargo Initiates Coverage On Pharvaris with Overweight Rating, Announces Price Target of $55 Wells Fargo analyst Yanan Zhu initiates coverage on Pharvaris (NASDAQ:PHVS) with a Overweight rating and announces Price Target of $55.
benzinga.com Pharvaris Says FDA Accepts NDA For Deucrictibant IR Capsule (20 Mg) For On-Demand Treatment Of Hereditary Angioedema Attacks; PDUFA Target Action Date Set April 23, 2027 If approved, deucrictibant will be the first oral bradykinin B2 receptor antagonist to treat HAE attacksNDA includes positive data from successful clinical program demonstrating rapid relief and…